Liane Rapatoni

ORCID: 0000-0002-3523-2237
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HER2/EGFR in Cancer Research
  • Colorectal Cancer Treatments and Studies
  • Neuroendocrine Tumor Research Advances
  • Cancer Risks and Factors
  • Estrogen and related hormone effects
  • Gastric Cancer Management and Outcomes
  • Cancer Diagnosis and Treatment
  • Head and Neck Cancer Studies
  • Inflammatory Myopathies and Dermatomyositis
  • Cancer Treatment and Pharmacology
  • Genetic factors in colorectal cancer
  • Lung Cancer Research Studies
  • Soft tissue tumor case studies
  • Metabolism, Diabetes, and Cancer
  • Health Systems, Economic Evaluations, Quality of Life
  • Esophageal Cancer Research and Treatment
  • Organ Transplantation Techniques and Outcomes
  • Renal Transplantation Outcomes and Treatments
  • Chemotherapy-related skin toxicity
  • Colorectal and Anal Carcinomas
  • Cutaneous lymphoproliferative disorders research
  • Polyomavirus and related diseases
  • DNA Repair Mechanisms
  • Muscle Physiology and Disorders
  • Nutrition and Health in Aging

Universidade de São Paulo
2012-2025

Universidade de Ribeirão Preto
2025

Clinics Hospital of Ribeirão Preto
2015-2023

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2018-2022

Sociedade Brasileira de Oncologia Clínica
2022

Thomas Powles Tibor Csöszi Mustafa Özgüroĝlu Nobuaki Matsubara Lajos Géczi and 95 more Susanna Cheng Yves Fradet Stéphane Oudard Christof Vulsteke Rafael Morales‐Barrera Aude Fléchon Şeyda Gündüz Yohann Loriot Alejo Rodríguez‐Vida Ronac Mamtani Evan Y. Yu Kijoeng Nam Kentaro Imai Blanca Homet Moreno Ajjai Alva D. Cascallar Mirta Varela Mauricio Fernández Lazzaro Diego Kaen Gabriela Gatica David Hugo Flores Agustín Falco Matias Molina F. Van Aelst Christof Vulsteke Brieuc Sautois Jean‐Pascal Machiels Denis Schallier Leandro Brust Liane Rapatoni Sérgio Jobim Azevedo GISELE LOPES MARINHO João Paulo Holanda Soares Carlos Dzik Jamile Almeida Silva André P. Fay Joel Gingerich Yves Fradet Cristiano Ferrario Kylea Potvin Marie Vanhuyse Mahmoud Abdelsalam Susanna Cheng Christian Caglevic Felipe Reyes José Luis Leal Francisco Francisco Carolina Ibáñez Florence Joly Brigitte Laguerre Sylvain Ladoire Aude Fléchon Delphine Topart Olivier Huillard Stéphane Oudard Marine Gross‐Goupil Stéphane Culine Yohann Loriot Gwénaëlle Gravis Peter Reichardt Margitta Retz Jan Herden David G. Pfister Carsten Ohlman Michael Stöeckle Manfred P. Wirth Anja Lorch Günter Niegisch Peter J. Goebell Martin Boegemann Axel S. Merseburger Georgios Gakis Jens Bedke Andreas Neisius Christian A. Thomas Thomas Hoefner András Telekes Judit Kósa János Révész Gyorgy Bodoky Tibor Csöszi András Csejtei Lajos Géczi Ágnes Ruzsa Zsuzsanna Kolonics József Erfán Ray McDermott Richard Bambury Avishay Sella Stephen Jay Frank Daniel Kejzman Olesya Goldman Eli Rosenbaum Avivit Peer Raanan Berger

10.1016/s1470-2045(21)00152-2 article EN The Lancet Oncology 2021-05-26
Aditya Bardia Komal Jhaveri Seock‐Ah Im Sònia Pernas Michelino De Laurentiis and 95 more Shusen Wang Noelia Martínez-Jáñez Giuliano Borges David W. Cescon Masaya Hattori Yen‐Shen Lu Erika Hamilton Qingyuan Zhang Junji Tsurutani Kevin Kalinsky Pedro Emanuel Rubini Liedke Lu Xu Rick M. Fairhurst Sabrina S. Khan Neelima Denduluri Hope S. Rugo Binghe Xu Barbara Pistilli Betiana Romitelli Ernesto Korbenfeld Cristian Buono Arturo Barbero Geronimo Rosselli Sergio Daniele Sandra Anabel Ostoich Hans Wildiers Kevin Punie Joëlle Collignon Guy Jérusalem Andrea Gombos Giuliano Borges Pedro Emanuel Rubini Liedke Marcelle Goldner Cesca Patrícia Medeiros Milhomem Beato Laura Testa Hélio Pinczowski Liane Rapatoni Debora Jardim José Bines David W. Cescon Jamil Asselah Andre Blais Joanne Yu Jennifer Friedmann Cristiano Ferrario Binghe Xu Shusen Wang Qingyuan Zhang ZeFei Jiang Zhongsheng Tong Quchang Ouyang Jingfen Wang Tingjing Yao Yongsheng Wang Xiaojia Wang Meili Sun Hui Li Shu Wang Yuan Sheng Aimin Zang Zhang Zhanmin Wenyan Chen Xian Wang Zhong Ouyang Wěi Li Barbara Pistilli Thomas Bachelot Mony Ung Cristian Villanueva Delphine Garbay Anne-Claire Hardy-Bessard Audrey Mailliez Stéphanie Becourt William Mina Thomas Decker Julia Radosa Andreas Schneeweiß Michael Braun Bahriye Aktas Gábor Rubovszky Zsuzsanna Pápai Tibor Csöszi Yousuf Al-Farhat Ankit Patel Vineet Govinda Gupta Richu Sharma Chandrakanth Mosale Venkatesha Shailesh Bondarde Somnath Roy Nikhil Ghadyalpatil Lalit Sen Sharma Rajani Priya Yedla Michelino De Laurentiis Ida Paris Claudio Zamagni

PURPOSE The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. METHODS Adult patients with inoperable/metastatic HR+/HER2‒ cancer, who had disease progression on endocrine therapy, for whom therapy was...

10.1200/jco.24.00920 article EN Journal of Clinical Oncology 2024-09-12

This study compared mirtazapine with megestrol in the management of cancer-related anorexia-cachexia syndrome patients advanced cancer. A randomized, double-blind, controlled clinical trial involving cancer and was performed. Participants received 30 mg/day or 320 for eight weeks. The primary endpoint effect on weight gain secondary endpoints were its appetite, muscle strength, physical performance, body composition, adverse events, medication adherence. Linear regression model mixed effects...

10.3390/cancers15143588 article EN Cancers 2023-07-12

448 Background: T-DXd is a HER2-directed antibody-drug conjugate; 6.4 mg/kg monotherapy approved for patients with metastatic HER2+ GC/GEJA who have received prior trastuzumab-based regimen. Preliminary results from DG-03 Part 2 showed feasibility and promising antitumor activity 1L (arm D) or 5.4 F) FP pembrolizumab in esophageal adenocarcinoma/GC/GEJA. was associated higher than expected toxicity; alternatively, early safety data triplet combination manageable profile. We report updated...

10.1200/jco.2025.43.4_suppl.448 article EN Journal of Clinical Oncology 2025-01-27

INTRODUCTION: Multiple stages of carcinogenesis in colon cancer encompass subpopulations stem cells (CSC), responsible for tumor cell transformation, growth and proliferation. CD44 CD166 proteins are CSC markers associated with signaling, adhesion, migration, metastasis lymph ocytic response. The expression may be modulated by some factors, such as the KRAS gene mutation. OBJECTIVE: Correlate metastatic adenocarcinoma mutation status (wild-type/mutated) clinical pathological features...

10.3233/cbm-160592 article EN Cancer Biomarkers 2016-04-13

Here, we describe the case of a patient diagnosed with locally advanced breast cancer 8 years ago. Her treatment course was neoadjuvant chemotherapy, followed by mastectomy and then adjuvant radiotherapy trastuzumab (TTZ). During use targeted therapy, an incidental pregnancy diagnosed. Four later, she developed bone cerebral metastases, since then, has received courses TTZ, capecitabine, lapatinib, intermittent control disease. 7-year-old son presents normal physical long-term neurological...

10.1097/cad.0000000000000344 article EN Anti-Cancer Drugs 2016-01-31

KRAS gene mutations play an important role in the carcinogenesis of colorectal tumors. However, studies that have assessed association between mutation status and disease characteristics report conflicting results. To assess (mutated or wild-type) its with clinical, epidemiological, histopathological features metastatic adenocarcinoma as well clinical outcomes.Cross-sectional descriptive study which data were collected from medical records 65 patients diagnosed at Clinical Oncology Service...

10.4021/wjon719w article EN cc-by-nc World Journal of Oncology 2013-01-01

Abstract Polygenic risk scores (PRS) quantify the genetic of diseases based on alleles in genomic loci identified genome-wide association studies (GWAS). As individuals European ancestry are overrepresented GWAS, PRS performance may vary different ancestries. Brazil is largest and most populated country Latin America, with around 43% admixed individuals, data breast cancer for this population lacking. We aimed to evaluate a 313 SNPs generated Europeans Brazilian population. In case-control...

10.1158/1538-7445.sabcs23-po2-08-03 article EN Cancer Research 2024-05-02

Collecting duct carcinoma (CDC) is a rare disease associated with high mortality rate. The present study describes the case of recipient kidney transplant metastatic allograft CDC whose treatment was successful. patient underwent nephrectomy, and chemotherapy gemcitabine cisplatin, while undergoing haemodialysis remained in remission after 6 years follow-up. There lack information about clinical management CDC; however, combination cisplatin remains as first-line therapy. challenge this...

10.3892/ol.2024.14661 article EN Oncology Letters 2024-09-03

Cancer-related fatigue is characterized by feelings of extreme tiredness, which do not improve with rest and negatively affects the physical psychosocial function patients, significantly reducing their quality life.The prevalence in cancer patients undergoing chemotherapy can be as high 90%.Colorectal one neoplasms highest incidence cancer-related fatigue, especially among individuals older than 65 years old.To perform a comparative assessment ofcancer-related colorectal during first four...

10.15761/icst.1000115 article EN cc-by Integrative Cancer Science and Therapeutics 2015-01-01

Bloom's syndrome is a rare disease that related to an increased risk of developing malignant neoplasm.The patient reported was followed up with several hospital staff when she diagnosed gastric cancer, but unfortunately, had already peritoneal implants in moment the surgery approach.It has been literature patients this present greater toxicity chemotherapeutic treatment, however due rarity disease, it not known exactly how adjustment these drugs should be performed and which better protocol...

10.17265/2328-2150/2017.07.006 article EN cc-by-nc Journal of Pharmacy and Pharmacology 2017-07-25

We report a case of paraneoplastic dermatomyositis in patient with diagnosis neuroendocrine tumor an unknown primary site.A 49-year-old woman, hypertensive, was admitted to our hospital due mass detected by abdominal computed tomography, contact the liver and gallbladder, having compressive effect on inferior vena cava, measuring 10.4 x 7.3 7.8 cm.Pathological examination showed signet-ring cell neoplasm ki-67 proliferation index 60%, microscopic immunohistochemical findings indicated...

10.15761/ccrr.1000138 article EN cc-by Clinical Case Reports and Reviews 2015-01-01

Obesity is a growing clinical condition around the world, considered risk factor for numerous diseases such as hypertension, myocardial infarction, diabetes, and cancer.Among neoplasms related to overweight, breast cancer stands out.Therefore, objective of this review elucidate impact obesity on most prevalent among women, either direct its onset or determinant survival.

10.29289/z2594539420180000196 article EN Mastology 2018-03-01

e15190 Background: Gastric cancer is a common malignant disease with high mortality rate. Neoadjuvant treatment efficient, but not the first option for in all countries. Studies of neadjuvant chemotherapy gastric South American countries are lacking. The aim this retrospective analysis was to investigate use ECX (epirubicin, cisplatin, and capecitabine) regimen neoadjuvant therapy Brazilian population. Methods: 25 patients (median age, 61; range 36-78 years; 14 pts >60 years) locally...

10.1200/jco.2013.31.15_suppl.e15190 article EN Journal of Clinical Oncology 2013-05-20

650 Background: Neuroendocrine tumors are rare malignant neoplasms derived from endocrine cells and known for their heterogeneous behavior histopathological characteristics; however, largely associated with a favorable clinical outcome. Somatostatin analogues (SSA) were initially used to control the symptoms of secretory neuroendocrine tumors, later, they considered effective as first-line systemic treatment in unresectable or metastatic gastroenteropancreatic tract (NET-GEP). Randomized...

10.1200/jco.2023.41.4_suppl.650 article EN Journal of Clinical Oncology 2023-01-24

Os tumores neuroendócrinos primários de mama (TNPMs) são incomuns e não há consenso quanto a tratamento prognóstico. No presente trabalho, foram revisados os diagnósticos 1.184 pacientes com câncer atendidos no Hospital das Clínicas da Faculdade Medicina Ribeirão Preto Universidade São Paulo (HCFMRP/USP), identificando três casos que preenchiam critérios TNPM, segundo classificação estabelecida pela Organização Mundial Saúde (OMS) em 2003. Foram avaliados achados clinicopatológicos...

10.1590/s1676-24442012000200012 article PT cc-by Jornal Brasileiro de Patologia e Medicina Laboratorial 2012-04-01

10.1055/s-0038-1674987 article PT cc-by International Journal of Nutrology 2018-09-01

Introduction: Head and neck cancer (HNC) is a heterogeneous group of neoplasms that can have poor prognosis when diagnosed in advanced stages. The optimized treatment for locally unresectable lesions mainly based on radiotherapy associated with chemotherapy (cisplatin 100mg/m²), however, at the expense high toxicity index. Objective: Evaluate whether chemoradiotherapy (CRT) – goldstandard head effective study population. Methods: This retrospective aimed determining efficacy definitive...

10.4322/ahns.2022.0004 article EN Archives of Head and Neck Surgery 2022-01-01
Coming Soon ...